BR112021020450A2 - Processos para fabricação e uso de um secretoma derivado de células-tronco mesenquimais - Google Patents
Processos para fabricação e uso de um secretoma derivado de células-tronco mesenquimaisInfo
- Publication number
- BR112021020450A2 BR112021020450A2 BR112021020450A BR112021020450A BR112021020450A2 BR 112021020450 A2 BR112021020450 A2 BR 112021020450A2 BR 112021020450 A BR112021020450 A BR 112021020450A BR 112021020450 A BR112021020450 A BR 112021020450A BR 112021020450 A2 BR112021020450 A2 BR 112021020450A2
- Authority
- BR
- Brazil
- Prior art keywords
- mesenchymal stem
- processes
- manufacturing
- stem cell
- secretome
- Prior art date
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2053—IL-8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
Abstract
processos para fabricação e uso de um secretoma derivado de células-tronco mesenquimais. o presente pedido fornece métodos e processos para fabricação e uso de um secretoma de células-tronco mesenquimais, bem como métodos para tratar condições e distúrbios oculares com o secretoma de células-tronco mesenquimais aqui descrito.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962831371P | 2019-04-09 | 2019-04-09 | |
US201962929035P | 2019-10-31 | 2019-10-31 | |
US16/785,463 US10881693B2 (en) | 2019-04-09 | 2020-02-07 | Processes for making and using a mesenchymal stem cell derived secretome |
US16/785,470 US10758571B1 (en) | 2019-04-09 | 2020-02-07 | Processes for making and using a mesenchymal stem cell derived secretome |
PCT/US2020/027093 WO2020210248A1 (en) | 2019-04-09 | 2020-04-07 | Processes for making and using a mesenchymal stem cell derived secretome |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021020450A2 true BR112021020450A2 (pt) | 2021-12-14 |
Family
ID=72241604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021020450A BR112021020450A2 (pt) | 2019-04-09 | 2020-04-07 | Processos para fabricação e uso de um secretoma derivado de células-tronco mesenquimais |
Country Status (11)
Country | Link |
---|---|
US (5) | US10758571B1 (pt) |
EP (1) | EP3952892A4 (pt) |
JP (1) | JP2022526855A (pt) |
KR (1) | KR20220047210A (pt) |
CN (1) | CN114269359A (pt) |
AU (1) | AU2020270892A1 (pt) |
BR (1) | BR112021020450A2 (pt) |
CA (1) | CA3136614A1 (pt) |
CL (1) | CL2021002655A1 (pt) |
MX (1) | MX2021012461A (pt) |
WO (1) | WO2020210248A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10758571B1 (en) | 2019-04-09 | 2020-09-01 | Combangio, Inc. | Processes for making and using a mesenchymal stem cell derived secretome |
IT201900022029A1 (it) * | 2019-11-25 | 2021-05-25 | Dompe Farm Spa | Formulazioni oftalmiche |
WO2021123320A1 (en) * | 2019-12-20 | 2021-06-24 | Dr. Kalali Prof. Mostafazadeh Dipl. Ing. Miedl (Kmm) Gesellschaft Bürgerlichen Rechts | A composition and its use for a universal therapy against tumor cells |
US20210369617A1 (en) * | 2020-04-07 | 2021-12-02 | Combangio, Inc. | Lyophilized mesenchymal stem cell derived secretome and uses thereof |
EP3970732A1 (en) * | 2020-09-17 | 2022-03-23 | Hunan Yuanpin Cell Technology Co. Ltd | Use of mesenchymal stem cells in the treatment of viral infections and/or complications caused by viral infections |
CN112656816A (zh) * | 2021-01-15 | 2021-04-16 | 浙江大学 | 一种负载外泌体的纤维蛋白胶及其应用 |
US20220378846A1 (en) * | 2021-06-01 | 2022-12-01 | U-Neuron Biomedical Inc. | Use of secretome of amniotic fluid stem cell in the treatment of dry eye disease |
CN113583950A (zh) * | 2021-08-06 | 2021-11-02 | 合肥滴碧云生物科技有限公司 | 一种制备干细胞活性因子的方法及其应用 |
CN114350603B (zh) * | 2022-01-23 | 2022-08-23 | 上海揽微赛尔生物科技有限公司 | 包含外泌体的间充质干细胞胞外基质及其制备和在细胞修复中的应用 |
CN115282286B (zh) * | 2022-02-09 | 2023-05-02 | 天津医科大学眼科医院 | 一种治疗眼部新生血管类疾病的纳米复合体及应用 |
US20240012011A1 (en) * | 2022-07-08 | 2024-01-11 | Combangio, Inc. | Methods and assays for secretome activity analysis |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
WO2006060779A2 (en) | 2004-12-03 | 2006-06-08 | Case Western Reserve University | Novel methods, compositions and devices for inducing neovascularization |
US20060222634A1 (en) | 2005-03-31 | 2006-10-05 | Clarke Diana L | Amnion-derived cell compositions, methods of making and uses thereof |
US8871198B2 (en) | 2006-03-29 | 2014-10-28 | Stemnion, Inc. | Methods related to wound healing |
EP2617428A1 (en) | 2006-08-15 | 2013-07-24 | Agency for Science, Technology and Research | Mesenchymal stem cell conditioned medium |
US8021882B2 (en) | 2006-08-24 | 2011-09-20 | Johnstone Brian H | Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith |
WO2009045359A1 (en) | 2007-10-01 | 2009-04-09 | Stemnion, Inc. | Skin replacement compositions and methods |
CN104623669A (zh) | 2007-08-22 | 2015-05-20 | 斯丹姆涅恩有限公司 | 含细胞因子溶液的新组合物 |
PL2254586T3 (pl) | 2008-02-22 | 2015-09-30 | Agency For Science Tech And Research Astarstar | Cząstki mezenchymalnych komórek macierzystych |
US20110158958A1 (en) | 2009-12-07 | 2011-06-30 | Sing George L | Methods for treating ophthalmic disorders, diseases and injuries |
WO2010110768A1 (en) | 2009-03-23 | 2010-09-30 | Regenetech, Inc. | Composition and method for producing composition for constructing tissue, and tissue construct |
EP2251028A1 (en) * | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
KR101834019B1 (ko) | 2009-07-10 | 2018-03-02 | 히스토젠, 인코포레이티드 | 저산소 조건 하에 배양된 세포로부터의 조정 배지 및 세포외 기질 조성물 |
US20110206647A1 (en) * | 2010-02-25 | 2011-08-25 | Abt Holding Company | Modulation of Angiogenesis |
WO2011127090A1 (en) | 2010-04-05 | 2011-10-13 | Medstar Health Research Institute, Inc. | Conditioned medium obtained form stem cells and its use in therapy |
FR2974201B1 (fr) | 2011-04-18 | 2013-04-12 | Inside Secure | Circuit de multiplication de montgomery |
US20120276215A1 (en) | 2011-04-26 | 2012-11-01 | Riordan Neil H | Therapeutic Conditioned Media |
US9950016B2 (en) | 2011-06-24 | 2018-04-24 | National University Of Ireland, Galway | Cell secreted proteins for the treatment of myocardial infarction |
ITTO20111183A1 (it) | 2011-12-21 | 2013-06-22 | Univ Degli Studi Torino | Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia |
CN104204192A (zh) | 2012-02-13 | 2014-12-10 | 加米达细胞有限公司 | 间充质干细胞调理的基质及其产生和使用方法 |
ITTO20120859A1 (it) | 2012-10-02 | 2014-04-03 | Univ Degli Studi Torino | Nuova applicazione terapeutica di un mezzo condizionato da cellule staminali mesenchimali placentari |
CN103767985A (zh) * | 2012-10-22 | 2014-05-07 | 吉林省霍普金斯药物研究院有限责任公司 | 人源血液或间充质干细胞分泌exosome的制备与应用 |
ES2963968T3 (es) | 2013-01-09 | 2024-04-03 | United Therapeutics Corp | Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas |
US20140242043A1 (en) | 2013-02-23 | 2014-08-28 | Stemnion, Inc. | Methods for preventing or treating optic neuritis |
US20140255355A1 (en) | 2013-03-07 | 2014-09-11 | Stemnion, Inc. | Methods for treating blepharitis |
CL2013003066A1 (es) | 2013-10-22 | 2014-07-25 | Univ Chile | Composicion para tratamiento de heridas porque comprende matriz soporte y células troncalesmesenquiámicas de gelatina de wharton; metodo para tratar heridas que comprende aplicar dicha composicion |
US9636364B2 (en) | 2013-12-04 | 2017-05-02 | Stemnion, Inc. | Methods for treating ocular contusion and blunt injury and traumatic injury to the optic nerve |
US9464272B2 (en) | 2013-12-12 | 2016-10-11 | Stemnion, Inc. | Cell-derived composition |
WO2015179490A1 (en) | 2014-05-21 | 2015-11-26 | Stemnion, Inc. | Treatment of diseases and conditions caused by increased vascular permeability |
EP3224348B1 (en) | 2014-11-27 | 2021-07-14 | Med Cell Bahamas Ltd. | Secretomes and method for producing secretomes |
WO2016082882A1 (en) | 2014-11-27 | 2016-06-02 | Med Cell Europe Ag | Secretomes and method for producing secretomes |
US20180327713A1 (en) | 2014-12-16 | 2018-11-15 | Janssen Biotech, Inc. | Treatment of retinal degeneration using progenitor cells |
RU2017124983A (ru) | 2014-12-16 | 2019-01-17 | Янссен Байотек, Инк. | Лечение дегенерации сетчатки с использованием клеток-предшественников |
US20170080033A1 (en) | 2014-12-16 | 2017-03-23 | Janssen Biotech, Inc. | Treatment of retinal degeneration using progenitor cells |
KR101566450B1 (ko) | 2015-04-03 | 2015-11-05 | (유)스템메디케어 | 중간엽 줄기세포에서 단백질의 대량 생산 방법 |
TWI741980B (zh) * | 2015-04-07 | 2021-10-11 | 大陸商四川藍光英諾生物科技股份有限公司 | 一種生物磚及其用途 |
US20160361253A1 (en) | 2015-06-13 | 2016-12-15 | Noveome Biotherapeutics, Inc. | Novel Methods for Delivering Therapeutic Agents to the Eye via Nasal Passages |
WO2017001649A1 (en) | 2015-07-02 | 2017-01-05 | Med Cell Europe Ag | Secretomes and method for producing secretomes |
US20180220642A1 (en) | 2015-07-29 | 2018-08-09 | Indiana University Research And Technology Corporation | Materials and methods for treating and evaluating ischemic and/or reperfusion-injured tissue and/or tissue susceptible to same |
CN109072189A (zh) | 2016-02-12 | 2018-12-21 | 细胞治疗药物公司 | 脂肪组织衍生的间充质基质细胞条件培养基及其制备和使用方法 |
KR20170111057A (ko) | 2016-03-25 | 2017-10-12 | (주)안트로젠 | 면역 질환 또는 염증성 질환의 예방 또는 치료용 중간엽줄기세포 배양액 및 이의 제조방법 |
RU2708329C2 (ru) | 2016-05-31 | 2019-12-05 | Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" | Материал стволовых клеток, композиции и способы применения |
WO2017217967A1 (en) | 2016-06-13 | 2017-12-21 | Noveome Biotherapeutics, Inc. | Novel methods for delivering therapeutic agents to the eye via nasal passages |
US20180028570A1 (en) | 2016-08-01 | 2018-02-01 | Ucl Business Plc | Angiogenic Factors |
KR20180024223A (ko) * | 2016-08-29 | 2018-03-08 | 사회복지법인 삼성생명공익재단 | 중간엽 줄기세포 분비 단백질을 포함하는 말초신경 세포 증식 촉진용 조성물 |
CN110087658A (zh) | 2016-10-12 | 2019-08-02 | 新加坡科技研究局 | 一种用于冻干外泌体的方法 |
WO2018102174A1 (en) | 2016-12-01 | 2018-06-07 | Janssen Biotech, Inc. | Treatment of retinal degeneration using progenitor cells |
WO2018131003A1 (en) | 2017-01-16 | 2018-07-19 | Cells For Cells, S.A | Composition comprising a substantially pure population of multipotent stromal cells encapsulated in platelet-poor plasma (ppp) |
US20180271914A1 (en) | 2017-03-21 | 2018-09-27 | Noveome Biotherapeutics, Inc. | Methods for Reducing the Extent of Light-induced Tissue Inflammation and Injury |
WO2018213795A1 (en) | 2017-05-18 | 2018-11-22 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted in situ therapeutic delivery of secreted factors from stem cells for treatment of damaged tissue |
WO2019016799A1 (en) | 2017-07-16 | 2019-01-24 | Ramot At Tel-Aviv University Ltd. | SECRETEOME OF HUMAN MUCOSAL MUCOSAL STEM CELLS |
US10364270B2 (en) | 2017-10-02 | 2019-07-30 | Pro Sunfun Biotech Research And Developmment Co., Ltd. | Eye-care peptide, its composition and method of using the same |
CN108517002A (zh) * | 2018-04-20 | 2018-09-11 | 命之本源医疗科技(北京)有限公司 | 一种干细胞培养上清分泌蛋白的稳定剂 |
US10758571B1 (en) | 2019-04-09 | 2020-09-01 | Combangio, Inc. | Processes for making and using a mesenchymal stem cell derived secretome |
-
2020
- 2020-02-07 US US16/785,470 patent/US10758571B1/en active Active
- 2020-02-07 US US16/785,463 patent/US10881693B2/en active Active
- 2020-04-07 AU AU2020270892A patent/AU2020270892A1/en active Pending
- 2020-04-07 KR KR1020217036569A patent/KR20220047210A/ko not_active Application Discontinuation
- 2020-04-07 EP EP20788534.4A patent/EP3952892A4/en active Pending
- 2020-04-07 MX MX2021012461A patent/MX2021012461A/es unknown
- 2020-04-07 CA CA3136614A patent/CA3136614A1/en active Pending
- 2020-04-07 JP JP2021560632A patent/JP2022526855A/ja active Pending
- 2020-04-07 BR BR112021020450A patent/BR112021020450A2/pt unknown
- 2020-04-07 CN CN202080041151.5A patent/CN114269359A/zh active Pending
- 2020-04-07 WO PCT/US2020/027093 patent/WO2020210248A1/en unknown
- 2020-04-07 US US16/842,696 patent/US11654160B2/en active Active
-
2021
- 2021-02-25 US US17/185,801 patent/US11129853B2/en active Active
- 2021-10-12 CL CL2021002655A patent/CL2021002655A1/es unknown
-
2023
- 2023-04-17 US US18/301,947 patent/US20240033297A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3952892A1 (en) | 2022-02-16 |
JP2022526855A (ja) | 2022-05-26 |
AU2020270892A1 (en) | 2021-12-02 |
US11654160B2 (en) | 2023-05-23 |
CN114269359A (zh) | 2022-04-01 |
US20210187034A1 (en) | 2021-06-24 |
MX2021012461A (es) | 2022-01-04 |
US10758571B1 (en) | 2020-09-01 |
KR20220047210A (ko) | 2022-04-15 |
US10881693B2 (en) | 2021-01-05 |
WO2020210248A1 (en) | 2020-10-15 |
US11129853B2 (en) | 2021-09-28 |
CL2021002655A1 (es) | 2023-01-20 |
US20200325452A1 (en) | 2020-10-15 |
CA3136614A1 (en) | 2020-10-15 |
US20240033297A1 (en) | 2024-02-01 |
EP3952892A4 (en) | 2023-01-25 |
US20210052656A1 (en) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021020450A2 (pt) | Processos para fabricação e uso de um secretoma derivado de células-tronco mesenquimais | |
UY37495A (es) | Dinucleótidos cíclicos como agonistas de sting | |
TWD198905S (zh) | 無柵線太陽能電池 | |
CL2018002140A1 (es) | Métodos y composiciones para aumentar la eficiencia de modificación genética dirigida usando reparación genética mediada por oligonucleótidos | |
CO2019011462A2 (es) | Tratamiento para el asma con anticuerpo anti-tslp | |
PE20201263A1 (es) | Suministro de cargas utiles a las celulas madre | |
EP3493311A4 (en) | MEMBRANE ELECTRODES ARRANGEMENT, METHOD FOR PRODUCING THE SAME AND FUEL CELL THEREFOR | |
EA201692273A1 (ru) | Заменяющие клапаны сердца и способы их применения и изготовления | |
EP3648218A4 (en) | MEMBRANE-ELECTRODE ASSEMBLY, ITS MANUFACTURING PROCESS, AND FUEL CELL INCLUDING IT | |
AR117770A1 (es) | Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos | |
EA201992795A1 (ru) | Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе | |
CO2021001064A2 (es) | Método para la producción de las células t gamma delta | |
BR112021008738A2 (pt) | Processo para produzir células t geneticamente construídas | |
EA201791844A1 (ru) | Ядерный шаровой тепловыделяющий элемент и способ его изготовления | |
WO2015006725A3 (en) | Generation of induced pluripotent stem cells from normal human mammary epithelial cells | |
BR112018069506A2 (pt) | métodos para transfectar plantas e para reduzir eventos de integração aleatória | |
EP3536664A4 (en) | METHOD FOR PRODUCING AN ELECTRODE, ELECTRODE PRODUCED BY THIS, MEMBRANE ELECTRODE ARRANGEMENT WITH THE ELECTRODE, AND FUEL CELL WITH THE MEMBRANE ELECTRODE ARRANGEMENT | |
MX2022000893A (es) | Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas. | |
BR112018001814A2 (pt) | unidade móvel de produção de implante | |
BR112019003771A2 (pt) | método para fabricar um componente de combustível | |
AR113150A1 (es) | Producción mejorada de etanol libre de glicerol | |
EP3520892A4 (en) | SUPPORT, ELECTRODE FOR FUEL CELL, MEMBRANE-ELECTRODE ASSEMBLY, AND FUEL CELL COMPRISING SAME | |
CY1123144T1 (el) | Επαγωγη καρδιακης αναγεννησης μe microrna | |
KR102387596B9 (ko) | 촉매, 이의 제조 방법, 이를 포함하는 전극, 이를 포함하는 막-전극 어셈블리, 및 이를 포함하는 연료 전지 | |
KR102407694B9 (ko) | 촉매, 그 제조방법, 그것을 포함하는 전극, 그것을 포함하는 막-전극 어셈블리, 및 그것을 포함하는 연료 전지 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: COMBANGIO, INC. (US) |